Indivior Pharmaceuticals Inc 2026年季度报告

FORM 10-Q ☑QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended June30, 2026OR☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934Commission file number: 001-37835 Indivior Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) 98-1204773(I.R.S. Employer IdentificationNo.) Delaware 10710 Midlothian Turnpike, Suite 125North Chesterfield, VA 23235(address of principal executive offices)(zip code)Registrant's telephone number, including area code:(804) 379-1090 Securities Registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) hasbeen subject to such filing requirements for the past 90 days. Yes☑No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant wasrequired to submit such files). Yes☑No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,”and "emerging growth company" in Rule 12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☑ As of July28, 2026, the number of shares of common stock outstanding was 118,013,649. Table of Contents Table of ContentsPART I - FINANCIAL INFORMATIONItem 1. Unaudited Condensed Financial Statements.Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.Item 3. Quantitative and Qualitative Disclosures About Market Risk.Item 4. Controls and ProceduresPART II - OTHER INFORMATIONItem 1. Legal Proceedings.Item 1A. Risk Factors.Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.Item 3. Defaults Upon Senior Securities.Item 4. Mine Safety Disclosures.Item 5. Other Information.Item 6. Exhibits.SIGNATURES Important cautionary note regarding forward-looking statements Certain statements contained herein, as well as in other filings we make with the SEC and other written and oralinformation we release, regarding our performance or other events or developments in the future constitute “forward-lookingstatements” as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, amongother things, express and implied statements pertaining to the Company’s financial guidance; expected levels of future rebatepayments, research and development expenses; expected future capital expenditures; potential future share repurchases;anticipated benefits of the proposed merger with Supernus, the expected timing of completion of the proposed merger,estimated costs associated with the proposed merger; expectations regarding the adequacy of the Company’s current andexpected future liquidity to satisfy future cash requirements; expected litigation outcomes; and statements containing thewords "believe," "anticipate," "plan," "expect," "intend," "estimate," "forecast," "strategy," "target," "goal," "guidance," "outlook,""potential," "project," "priority," "may," "will," "should," "would," "could," "can," the negatives thereof, and variations thereon andsimilar expressions. By their nature, forward-looking statements involve risks and uncertainties as they relate to events orcircumstances that may or may not occur in the future. Actual results may differ materially from those expressed or implied in these forward-looking statements due to a numberof factors, including but not limited to: lower than expected future sales of our products; greater than expected impacts fromcompetition; and unanticipated costs including the effects of potential tariffs and potential retaliatory tariffs; market conditions;the decisions of third parties outside of our control with respect to potential business development opportunities; the risk thatthe proposed merger with Supernus may not be completed on the anticipated timeline or at all; the failure to obtain requiredstockholder or regulatory approvals for the merger, or the imposition of conditions in connection with such approvals; the riskthat the anticipated benefits, synergies, growth, profitability,